Provvedini D, Cohen P
Laboratoires Negma-Lerads, Toussus le Noble, France.
Presse Med. 2002 Dec 7;31(39 Pt 2):4S13-5.
SYMPTOMATIC EFFECTS OF DIACEREIN: Data obtained from several clinical trials have demonstrated that relief of joint pain obtained with the interleukin-1 inhibitor diacerein is comparable with that observed with non-steroidal anti-inflammatory drugs (NSAIDS) after four to six weeks of treatment and that relief persists after treatment withdrawal. Patients taking diacerein are less handicapped, use less NSAID and/or analgesics, and have lower demands for care as well as an improved quality of life. RADIOGRAPHIC FINDINGS: The ECHODIAH study conducted to evaluate the structure-modifying effect of diacerein in hip osteoarthritis.
Drug watch data and clinical trials have confirmed the safety and tolerance of diacerein, so there is no limitation on the duration of its use.
双醋瑞因的症状性疗效：多项临床试验获得的数据表明，使用白细胞介素-1抑制剂双醋瑞因缓解关节疼痛的效果在治疗四至六周后与非甾体抗炎药（NSAIDs）相当，且停药后缓解效果仍持续存在。服用双醋瑞因的患者残疾程度较低，使用的NSAIDs和/或镇痛药较少，护理需求较低，生活质量得到改善。影像学结果：ECHODIAH研究旨在评估双醋瑞因对髋骨关节炎的结构改善作用。
药物监测数据和临床试验已证实双醋瑞因的安全性和耐受性，因此其使用期限没有限制。
